B. Fitzharris

发表

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Fasting plasma lipid measurements following cisplatin chemotherapy in patients with germ cell tumors.

P. George, C. Atkinson, B. Robinson, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy with platinum compounds for metastatic colorectal cancer

M. Jeffery, P. Hider, R. Ng, 2003, Cochrane Database of Systematic Reviews.

Comparison of methods of assessment of renal function in patients with cancer treated with cisplatin, carboplatin or methotrexate.

C. Frampton, C. Atkinson, B. Robinson, 1990, Australian and New Zealand journal of medicine.

CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial

I. Vergote, H. Chalchal, E. Pujade-Lauraine, 2012, British Journal of Cancer.

Clinical examination, xeromammography, and fine-needle aspiration cytology in diagnosis of breast tumours.

T. Powles, J. Gazet, J. Williams, 1978, British medical journal.

Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort.

M. Atkins, A. Ribas, F. Hodi, 2016 .

Pembrolizumab plus ipilimumab for advanced melanoma : results of the keynote-029 expansion cohort

M. Atkins, A. Ribas, F. Hodi, 2016 .

Sources of proteins in human bile.

B. Mullock, M. Simpson, T. M. Hunt, 1985, Gut.

Carboplatin is ototoxic

C. Atkinson, B. Fitzharris, B. Colls, 2008, Cancer Chemotherapy and Pharmacology.

Surveillance for stage I non-seminomatous germ cell tumours of the testis: the optimal protocol has not yet been defined.

M. Tattersall, D. Raghavan, C. Atkinson, 1988, British journal of urology.

VP16-213 as a single agent in advanced testicular tumors.

A. Barrett, T. Mcelwain, S. Kaye, 1980, European journal of cancer.

Second malignant neoplasms in patients with Hodgkin's disease.

C. Atkinson, B. Robinson, B. Fitzharris, 1994, Australian and New Zealand journal of medicine.

A risk factor for relapse in Hodgkin's disease: Female gender?

C. Atkinson, B. Robinson, G. Jeffery, 1989, Hematological oncology.

AMINOGLUTETHIMIDE IN TREATMENT OF METASTATIC BREAST CARCINOMA

T. Powles, I. Smith, A. Neville, 1978, The Lancet.

Carcinoma in situ of the testis followed by an overt malignant teratoma of the testis within 12 months.

E. Arnold, S. Mark, B. Fitzharris, 1994, The Australian and New Zealand journal of surgery.

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.

M. Atkins, A. Ribas, F. Hodi, 2017, The Lancet. Oncology.

Surveillance for Stage I Non-Seminomatous Germ Cell Tumours of the Testis: The Optimal Protocol has not yet been Defined

M. Tattersall, D. Raghavan, C. Atkinson, 1989 .

Sources ofproteins inhumanbile

B. Mullock, T. M. Hunt, R. Hinton, 1985 .

Phase II study of carboplatin followed by sequential gemcitabine and paclitaxel as first-line treatment for advanced ovarian cancer

M. Friedlander, P. de Souza, M. Findlay, 2006, International Journal of Gynecologic Cancer.

Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: an Australian and New Zealand Gynaecological Oncology Group study

M. Links, R. Stuart-Harris, P. de Souza, 2006, International Journal of Gynecologic Cancer.

Plasma exchange v peritoneal dialysis for removing Bence Jones protein.

R. Corringham, R. Powles, J. Russell, 1978, British medical journal.

Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B

M. Atkins, A. Ribas, F. Hodi, 2020, Clinical Cancer Research.

Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer.

Val Gebski, Diana Zannino, M. Stockler, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Primary thyroid lymphoma: clinical features, treatment and outcome: a report of 8 cases.

J. Bremner, B. Fitzharris, J. Hamer, 1994, The New Zealand medical journal.

Australasian multicentre phase II study of paclitaxel (Taxol) in relapsed ovarian cancer.

M. Friedlander, I. Olver, K. Phillips, 1995, Australian and New Zealand journal of medicine.

Topical mitomycin C for the local treatment of a primary diffuse large B‐cell lymphoma of the palpebral conjunctiva

M. McKellar, B. Fitzharris, M. Elder, 2009, Clinical & experimental ophthalmology.

Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel--ANZGOG 02-01.

V. Gebski, A. Tinker, P. Beale, 2007, Gynecologic oncology.

B cell lymphoma presenting as carcinoma of the lung.

J. McKenzie, D. Hart, P. H. Fitzgerald, 1986, The New Zealand medical journal.

LYMPHOMA AFTER S.L.E.

J. Smyth, B. Fitzharris, A. Barrett, 1978, The Lancet.

COMPARATIVE ASPECTS OF THE HEPATOBILIARY TRANSPORT OF IgA *

B. Mullock, R. Hinton, B. Fitzharris, 1983, Annals of the New York Academy of Sciences.

Two cases of severe liver injury possibly related to 5‐fluorouracil and calcium folinate

E. Begg, B. Chapman, B. Fitzharris, 2007, Internal medicine journal.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

ANGIO‐IMMUNOBLASTIC LYMPHADENOPATHY WITH LUPUS ERYTHEMATOSUS CELLS

B. Gusterson, B. Fitzharris, 1979, British journal of haematology.

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.

M. Atkins, A. Ribas, F. Hodi, 2017, The Lancet. Oncology.